Rocket Pharmaceuticals Stock Surges 17% Premarket on FDA Alignment for Danon Disease Treatment
Shares of Rocket Pharmaceuticals surged 17.59% to $17.98 in premarket trading on Wednesday after the company said it reached alignment with the Food and Drug Administration regarding its Phase 2 trial for the treatment of Danon disease.The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of the investigational gene therapy RP-A501 to treat 12 patients with Danon disease.Danon is a rare genetic disorder that has no cure, and is known for weakening the heart and mo